Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial Meeting Abstract
| Authors: | Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J. W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; Tognon, G.; Chudecka-Glaz, A. M.; Berger, R.; Lheureux, S.; Henry, S.; Burges, A.; Wenham, R. M.; Nishio, S.; Marshall, L.; Harter, P. |
| Abstract Title: | Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S570 |
| End Page: | S571 |
| Language: | English |
| ACCESSION: | WOS:001326612901057 |
| DOI: | 10.1016/j.annonc.2024.08.812 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 751P -- Source: Wos |
